These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27870938)

  • 1. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.
    Llorens F; Kruse N; Schmitz M; Gotzmann N; Golanska E; Thüne K; Zejneli O; Kanata E; Knipper T; Cramm M; Lange P; Zafar S; Sikorska B; Liberski PP; Mitrova E; Varges D; Schmidt C; Sklaviadis T; Mollenhauer B; Zerr I
    Alzheimers Dement; 2017 Jun; 13(6):710-719. PubMed ID: 27870938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis.
    Kong Y; Chen Z; Wang X; Wang W; Zhang J
    J Alzheimers Dis; 2022; 89(2):493-503. PubMed ID: 35912746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.
    Llorens F; Kruse N; Karch A; Schmitz M; Zafar S; Gotzmann N; Sun T; Köchy S; Knipper T; Cramm M; Golanska E; Sikorska B; Liberski PP; Sánchez-Valle R; Fischer A; Mollenhauer B; Zerr I
    Mol Neurobiol; 2018 Mar; 55(3):2249-2257. PubMed ID: 28321768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease.
    Llorens F; Zafar S; Ansoleaga B; Shafiq M; Blanco R; Carmona M; Grau-Rivera O; Nos C; Gelpí E; Del Río JA; Zerr I; Ferrer I
    Neuropathol Appl Neurobiol; 2015 Aug; 41(5):631-45. PubMed ID: 25134744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.
    Zerr I; Schmitz M; Karch A; Villar-Piqué A; Kanata E; Golanska E; Díaz-Lucena D; Karsanidou A; Hermann P; Knipper T; Goebel S; Varges D; Sklaviadis T; Sikorska B; Liberski PP; Santana I; Ferrer I; Zetterberg H; Blennow K; Calero O; Calero M; Ladogana A; Sánchez-Valle R; Baldeiras I; Llorens F
    Alzheimers Dement; 2018 Jun; 14(6):751-763. PubMed ID: 29391125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases.
    Schmitz M; Villar-Piqué A; Hermann P; Escaramís G; Calero M; Chen C; Kruse N; Cramm M; Golanska E; Sikorska B; Liberski PP; Pocchiari M; Lange P; Stehmann C; Sarros S; Martí E; Baldeiras I; Santana I; Žáková D; Mitrová E; Dong XP; Collins S; Poleggi A; Ladogana A; Mollenhauer B; Kovacs GG; Geschwind MD; Sánchez-Valle R; Zerr I; Llorens F
    Brain; 2022 Apr; 145(2):700-712. PubMed ID: 35288744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic performance of CSF α-synuclein in prion disease in the context of rapidly progressive dementia.
    Mastrangelo A; Baiardi S; Zenesini C; Poleggi A; Mammana A; Polischi B; Ladogana A; Capellari S; Parchi P
    Alzheimers Dement (Amst); 2021; 13(1):e12214. PubMed ID: 34222611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.
    Oeckl P; Metzger F; Nagl M; von Arnim CA; Halbgebauer S; Steinacker P; Ludolph AC; Otto M
    Mol Cell Proteomics; 2016 Oct; 15(10):3126-3138. PubMed ID: 27507836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.
    Schmitz M; Villar-Piqué A; Llorens F; Gmitterová K; Hermann P; Varges D; Zafar S; Lingor P; Vanderstichele H; Demeyer L; Stoops E; Trojanowski JQ; Lee VM; Zerr I
    Mol Neurobiol; 2019 May; 56(5):3476-3483. PubMed ID: 30136097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach.
    Lee SM; Hyeon JW; Kim SJ; Kim H; Noh R; Kim S; Lee YS; Kim SY
    Prion; 2019 Jan; 13(1):141-150. PubMed ID: 31306078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
    Kasai T; Tokuda T; Ishii R; Ishigami N; Tsuboi Y; Nakagawa M; Mizuno T; El-Agnaf OM
    J Neurol; 2014 Jun; 261(6):1203-9. PubMed ID: 24737170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease.
    Abu-Rumeileh S; Oeckl P; Baiardi S; Halbgebauer S; Steinacker P; Capellari S; Otto M; Parchi P
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32218217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease.
    Llorens F; Villar-Piqué A; Hermann P; Schmitz M; Calero O; Stehmann C; Sarros S; Moda F; Ferrer I; Poleggi A; Pocchiari M; Catania M; Klotz S; O'Regan C; Brett F; Heffernan J; Ladogana A; Collins SJ; Calero M; Kovacs GG; Zerr I
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32059611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.
    Dorey A; Tholance Y; Vighetto A; Perret-Liaudet A; Lachman I; Krolak-Salmon P; Wagner U; Struyfs H; De Deyn PP; El-Moualij B; Zorzi W; Meyronet D; Streichenberger N; Engelborghs S; Kovacs GG; Quadrio I
    JAMA Neurol; 2015 Mar; 72(3):267-75. PubMed ID: 25559883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease.
    Kanata E; Golanska E; Villar-Piqué A; Karsanidou A; Dafou D; Xanthopoulos K; Schmitz M; Ferrer I; Karch A; Sikorska B; Liberski PP; Sklaviadis T; Zerr I; Llorens F
    J Clin Neurosci; 2019 Feb; 60():124-127. PubMed ID: 30309804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients.
    Zerr I; Villar-Piqué A; Schmitz VE; Poleggi A; Pocchiari M; Sánchez-Valle R; Calero M; Calero O; Baldeiras I; Santana I; Kovacs GG; Llorens F; Schmitz M
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31795176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.
    Skillbäck T; Rosén C; Asztely F; Mattsson N; Blennow K; Zetterberg H
    JAMA Neurol; 2014 Apr; 71(4):476-83. PubMed ID: 24566866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice.
    Fayolle M; Lehmann S; Delaby C
    J Neural Transm (Vienna); 2022 Feb; 129(2):133-139. PubMed ID: 35041062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.